人参皂苷相关代谢产物抗肿瘤机制的研究进展
Research progress on antitumor mechanism of ginsenoside⁃related metabolites
- 上海中医药大学学报 2023年37卷第3期 页码：83-91
- 作者机构：
1.上海上药神象健康药业有限公司（上海 200336）
2.上海中医药大学创新中药研究院（上海 201203）
- 作者简介：
陈丹青，女，硕士研究生，主要从事中药药效物质基础研究
王源，副研究员，硕士生导师；E-mail：amoness@163.com
- 基金信息：
DOI：10.16306/j.1008-861x.2023.03.014
中图分类号：
扫 描 看 全 文
陈丹青,郑艳艳,郭静等.人参皂苷相关代谢产物抗肿瘤机制的研究进展[J].上海中医药大学学报,2023,37(03):83-91.
CHEN Danqing,ZHENG Yanyan,GUO Jing,et al.Research progress on antitumor mechanism of ginsenoside⁃related metabolites[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):83-91.
陈丹青,郑艳艳,郭静等.人参皂苷相关代谢产物抗肿瘤机制的研究进展[J].上海中医药大学学报,2023,37(03):83-91. DOI： 10.16306/j.1008-861x.2023.03.014.
CHEN Danqing,ZHENG Yanyan,GUO Jing,et al.Research progress on antitumor mechanism of ginsenoside⁃related metabolites[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):83-91. DOI： 10.16306/j.1008-861x.2023.03.014.
摘要
人参作为名贵中药材，具有抗肿瘤等多种药理活性，其有效成分主要为人参皂苷。已知人参皂苷以达玛烷型四环三萜类皂苷为主，包括原人参二醇型和原人参三醇型皂苷。此类原型成分口服后难以直接被人体吸收利用，在肠道菌群作用下水解生成的次级人参皂苷或苷元才能被人体吸收利用。近年来研究显示，原人参二醇型皂苷主要通过肠道菌群转化为人参皂苷CK、Rh2和原人参二醇（PPD），而原人参三醇型皂苷则可经肠道菌群转化为人参皂苷Rh1、F1和PPT，其代谢产物往往表现出比原型人参皂苷更强的抗肿瘤活性。以人参皂苷在肠道菌群干预下的脱糖基作用为切入点，梳理归纳其代谢途径，并对相关代谢产物的抗肿瘤机制进行总结，为人参皂苷在抗肿瘤方面的开发应用提供科学依据。
Abstract
Ginseng， as a valuable traditional Chinese medicine， has a variety of pharmacological activities， and its active ingredient is mainly ginsenoside. Ginsenosides are mainly known as dammarane type tetracyclic triterpenoid saponins，including protopanaxadiol and protopanaxatriol saponins， which are difficult to be absorbed and utilized directly by human body after oral administration. But the scondary ginsenosides or aglycones generated by hydrolysis under the action of intestinal flora can be absorbed and utilized by the human body. Recent studies have shown that protopanaxadiol saponins can be converted into ginsenosides CK，Rh2 and protopanaxadiol （PPD） mainly by intestinal flora， while protopanaxatriol saponins can be converted into ginsenosides Rh1，F1 and PPT by intestinal flora，and the metabolites often show stronger antitumor activity than the prototype ginsenosides. The deglycosylation of ginsenosides by intestinal flora was used as an entry point to sort out their metabolic pathways and summarize the anti-tumor mechanisms of related metabolites，providing a scientific basis for the development and application of ginsenosides in antitumor fields.
关键词
人参皂苷肠道菌群代谢产物抗肿瘤
Keywords
ginsenosidesintestinal florametabolitesantitumor
references
PATEL S， RAUF A. Adaptogenic herb ginseng （Panax） as medical food： Status quo and future prospects［J］. Biomed Pharmacother， 2017， 85： 120-127.
CAO M， YAN H， HAN X， et al. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth［J］. J Immunother Cancer， 2019， 7（1）： 326.
HUANG J， LIU D， WANG Y， et al. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio， potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 （anti-PD-1/PD-L1） immunotherapy［J］. Gut， 2022， 71（4）： 734-745.
SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249.
LI X， CHU S， LIN M， et al. Anticancer property of ginsenoside Rh2 from ginseng［J］. Eur J Med Chem， 2020， 203： 112627.
MA J， GAO G， LU H， et al. Reversal effect of ginsenoside Rh2 on oxaliplatin-resistant colon cancer cells and its mechanism［J］. Exp Ther Med， 2019， 18（1）： 630-636.
CHU Y， ZHANG H C， LI S M， et al. Determination of ginsenoside Rc in rat plasma by LC-MS/MS and its application to a pharmacokinetic study［J］. J Chromatogr B Analyt Technol Biomed Life Sci， 2013， 919-920： 75-78.
WANG W， HA L， LI X， et al. Pharmacokinetic and metabolism study of ginsenoside Rb2 in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry［J］. Biomed Chromatogr， 2021， 35（11）： e5191.
YAO H， WAN J Y， ZENG J， et al. Effects of compound K， an enteric microbiome metabolite of ginseng， in the treatment of inflammation associated colon cancer［J］. Oncol Lett， 2018， 15（6）： 8339-8348.
SHIN B K， KWON S W， PARK J H. Chemical diversity of ginseng saponins from Panax ginseng［J］. J Ginseng Res， 2015， 39（4）： 287-298.
DABEK M， MCCRAE S I， STEVENS V J， et al. Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria［J］. FEMS Microbiol Ecol， 2008， 66（3）： 487-495.
KIM D H. Gut microbiota-mediated pharmacokinetics of ginseng saponins［J］. J Ginseng Res， 2018， 42（3）： 255-263.
KANG A， ZHANG S， ZHU D， et al. Gut microbiota in the pharmacokinetics and colonic deglycosylation metabolism of ginsenoside Rb1 in rats： Contrary effects of antimicrobials treatment and restraint stress［J］. Chem Biol Interact， 2016， 258： 187-196.
LEE S Y， YUK H G， KO S G， et al. Gut Microbiome prolongs an inhibitory effect of Korean red ginseng on high-fat-diet-induced mouse obesity［J］. Nutrients， 2021， 13（3）： 926.
AKAO T， KIDA H， KANAOKA M， et al. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. ［J］. J Pharm Pharmacol， 1998， 50（10）： 1155-1160.
BAE E A， PARK S Y， KIM D H. Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull， 2000， 23（12）： 1481-1485.
KIM K A， JUNG I H， PARK S H， et al. Comparative analysis of the gut microbiota in people with different levels of ginsenoside Rb1 degradation to compound K［J］. PLoS One， 2013， 8（4）： e62409.
KIM K A， YOO H H， GU W， et al. A prebiotic fiber increases the formation and subsequent absorption of compound K following oral administration of ginseng in rats［J］. J Ginseng Res， 2015， 39（2）： 183-187.
ZHENG F， ZHANG M Y， WU Y X， et al. Biotransformation of ginsenosides （Rb1 ， Rb2 ， Rb3 ， Rc） in human intestinal bacteria and its effect on intestinal flora. Chem Biodivers， 2021， 18（12）： e2100296.
BAE E A， CHOO M K， PARK E K， et al. Metabolism of ginsenoside R（c） by human intestinal bacteria and its related antiallergic activity［J］. Biol Pharm Bull， 2002， 25（6）： 743-747.
ZHANG C， XU Y， GU M， et al. Biotransformation of ginsenoside Rc to Rd by endophytic bacterium Bacillus sp. G9y isolated from Panax quinquefolius［J］. Antonie Van Leeuwenhoek， 2021， 114（4）： 437-444.
BAE E A， HAN M J， KIM E J， et al. Transformation of ginseng saponins to ginsenoside rh2 by acids and human intestinal bacteria and biological activities of their transformants［J］. Arch Pharm Res， 2004， 27： 61–67.
BAE E A， HAN M J， CHOO M， et al. Metabolism of 20（S）- and 20（R）-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities［J］. Biol Pharm Bull， 2002， 251： 58-63.
KIM U， PARK M H， KIM D H， et al. Metabolite profiling of ginsenoside Re in rat urine and faeces after oral administration［J］. Food Chem， 2013， 136（3-4）： 1364-1369.
BAE E A， SHIN J E， KIM D H. Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect［J］. Biol Pharm Bull， 2005， 28（10）： 1903-1908.
LIU L， HUANG J， HU X， et al. Simultaneous determination of ginsenoside （G-Re， G-Rg1， G-Rg2， G-F1， G-Rh1） and protopanaxatriol in human plasma and urine by LC-MS/MS and its application in a pharmacokinetics study of G-Re in volunteers［J］. J Chromatogr B Analyt Technol Biomed Life Sci， 2011， 879（22）： 2011-2017.
高霞， 耿婷， 马阳， 等. 离体大鼠肠道菌对6种皂苷类成分代谢研究［J］. 中国中药杂志， 2016， 41（12）： 2329-2338.
GAO X， GENG T， MA Y， et al. Metabolism of six sabonis by rat intestinal bacteria in vitro［J］. China Journal of Chinese Materia Medica， 2016， 41（12）： 2329-2338.
TAWAB M A， BAHR U， KARAS M， et al. Degradation of ginsenosides in humans after oral administration［J］. Drug Metab Dispos. 2003；31（8）：1065-1071
WANG X， WANG C， PU F， et al. Metabolite profiling of ginsenoside Rg1 after oral administration in rat［J］. Biomed Chromatogr， 2014， 28（10）： 1320-1324.
ZHOU W， FENG M Q， LI J Y， et al. Studies on the preparation， crystal structure and bioactivity of ginsenoside compound K［J］. J Asian Nat Prod Res， 2006， 8（6）： 519-527.
CHOI K， CHOI C. Proapoptotic ginsenosides compound K and Rh enhance Fas-induced cell death of human astrocytoma cells through distinct apoptotic signaling pathways［J］. Cancer Res Treat， 2009， 41（1）： 36-44.
LEE J H， LEE D Y， LEE H J， et al. Inhibition of STAT3/PD-L1 and activation of miR193a-5p are critically involved in apoptotic effect of compound K in prostate cancer cells［J］. Cells， 2021， 10（8）： 2151.
OH J M， KIM E， CHUN S. Ginsenoside compound K induces ros-mediated apoptosis and autophagic inhibition in hman nuroblastoma clls inVitro and in Vivo［J］. Int J Mol Sci， 2019， 20（17）： 4279.
SHIN D H， LEEM D G， SHIN J S， et al. Compound K induced apoptosis via endoplasmic reticulum Ca2+ release through ryanodine receptor in human lung cancer cells［J］. J Ginseng Res， 2018， 42（2）： 165-174.
YIN Q， CHEN H， MA R H， et al. Ginsenoside CK induces apoptosis of human cervical cancer HeLa cells by regulating autophagy and endoplasmic reticulum stress［J］. Food Funct， 2021， 12（12）： 5301-5316.
JO H， JANG D， PARK S K， et al. Ginsenoside 20（S）-protopanaxadiol induces cell death in human endometrial cancer cells via apoptosis［J］. J Ginseng Res， 2021， 45（1）： 126-133.
SCHWARTZ G K， SHAH M A. Targeting the cell cycle： a new approach to cancer therapy［J］. J Clin Oncol， 2005， 23（36）： 9408-9421.
HAN Q， HAN L， TIE F， et al. （20S）-Protopanaxadiol ginsenosides induced cytotoxicity via blockade of autophagic flux in HGC-27 Cells［J］. Chem Biodivers， 2020， 17（7）： e2000187.
YAO H， WAN J Y， ZENG J， et al. Effects of compound K， an enteric microbiome metabolite of ginseng， in the treatment of inflammation associated colon cancer. Oncol Lett， 2018， 15（6）：8339-8348.
XU X， LAI Y， HUA Z C. Apoptosis and apoptotic body： disease message and therapeutic target potentials. Biosci Rep， 2019， 39（1）： BSR20180992.
CHEN S， YE H， GONG F， et al. Ginsenoside compound K exerts antitumour effects in renal cell carcinoma via regulation of ROS and lncRNA THOR［J］. Oncol Rep， 2021， 45（4）： 38.
LI C， GAO H， FENG X， et al. Ginsenoside Rh2 impedes proliferation and migration and induces apoptosis by regulating NF-kappaB， MAPK， and PI3K/Akt/mTOR signaling pathways in osteosarcoma cells［J］. J Biochem Mol Toxicol， 2020， 34（12）： e22597.
WANG J， BIAN S， WANG S， et al. Ginsenoside Rh2 represses autophagy to promote cervical cancer cell apoptosis during starvation［J］. Chin Med， 2020， 15（1）： 118.
LEE S， KWON M C， JANG J P， et al. The ginsenoside metabolite compound K inhibits growth， migration and stemness of glioblastoma cells［J］. Int J Oncol， 2017， 51（2）： 414-424.
ZHANG S， ZHANG M， CHEN J， et al. Ginsenoside compound K regulates HIF-1α-Mediated glycolysis through bclaf1 to inhibit the proliferation of human liver cancer cells［J］. Frontiers in Pharmacology， 2020， 11： 583334.
SHIN N， LEE H J， SIM D Y， et al. Apoptotic effect of compound K in hepatocellular carcinoma cells via inhibition of glycolysis and Akt/mTOR/c‐Myc signaling［J］. Phytotherapy Research， 2021， 35（7）： 3812-3820.
KIM T J， KIM H J， KANG M， et al. Ginsenoside F2 induces cellular toxicity to glioblastoma through the impairment of mitochondrial function［J］. Phytomedicine， 2021， 83： 153483.
SHAO L， GUO Y P， WANG L， et al. Effects of ginsenoside compound K on colitis-associated colorectal cancer and gut microbiota profiles in mice［J］. Ann Transl Med， 2022， 10（7）： 408.
ZHANG J， MA X， FAN D. Ginsenoside CK inhibits hypoxia-induced epithelial-mesenchymal transformation through the HIF-1alpha/NF-kappaB feedback pathway in hepatocellular carcinoma［J］. Foods， 2021， 10（6）： 1195.
GE G， YAN Y， CAI H. Ginsenoside Rh2 inhibited proliferation by inducing ROS mediated ER stress dependent apoptosis in lung cancer cells［J］. Biol Pharm Bull， 2017， 40（12）： 2117-2124.
QIANG S Q， QIN G C， JING L， et al. Anticancer effect of Rh2， a histone deacetylase inhibitor， in HepG2 cells and HepG2 cell-derived xenograft tumors occurs via the inhibition of HDACs and activation of the MAPK signaling pathway［J］. Asian Pac J Cancer Prev， 2021， 22（8）： 2529-2539.
WANG M， YAN S J， ZHANG H T， et al. Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model［J］. Oncol Lett， 2017， 13（2）： 681-685.
LI S， GAO Y， MA W， et al. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2［J］. Tumour Biol， 2014， 35（6）： 5593-5598.
ZHANG E， SHI H， YANG L， et al. Ginsenoside Rd regulates the Akt/mTOR/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth［J］. Oncol Rep， 2017， 38（1）： 359-367.
LI Y， WANG P， ZOU Z， et al. Ginsenoside （20S）-protop-anaxatriol induces non-protective autophagy and apoptosis by inhibiting Akt/mTOR signaling pathway in triple-negative breast cancer cells［J］. Biochem Biophys Res Commun， 2021， 583： 184-191.
CHEN K， JIAO J， XUE J， et al. Ginsenoside CK induces apoptosis and suppresses proliferation and invasion of human osteosarcoma cells through the PI3K/mTOR/p70S6K1 pathway［J］. Oncol Rep， 2020， 43（3）： 886-896.
HUANG J， PAN D， LIU F， et al. Ginsenoside compound K inhibits the proliferation， migration and invasion of Eca109 cell via VEGF-A/Pi3k/Akt pathway［J］. J Cardiothorac Surg， 2022， 17（1）： 99.
CHEN Y， ZHANG Y， SONG W， et al. Ginsenoside Rh2 inhibits migration of lung cancer cells under hypoxia via mir-491［J］. Anticancer Agents Med Chem， 2019， 19（13）： 1633-1641.
JIANG S， YAN J， CHEN X， et al. Ginsenoside Rh2 inhibits thyroid cancer cell migration and proliferation via activation of miR-524-5p［J］. Arch Med Sci， 2022， 18（1）： 164-170.
WEI W， GUO Q， GUO C， et al. Ginsenoside Rh2 suppresses metastasis and growth of colon cancer via miR-491［J］. J Oncol， 2021， 2021： 1-7.
ZHANG G， HE L， CHEN J， et al. Ginsenoside Rh2 activates alpha-catenin phosphorylation to inhibit lung cancer cell proliferation and invasion［J］. Exp Ther Med， 2020， 19（4）： 2913-2922.
PENG B， HE R， XU Q， et al. Ginsenoside 20（S）-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway［J］. Pharmacol Res， 2019， 142： 1-13.
LI W， WANG Y， ZHOU X， et al. The anti-tumor efficacy of 20（S）-protopanaxadiol， an active metabolite of ginseng， according to fasting on hepatocellular carcinoma［J］. J Ginseng Res， 2022， 46（1）： 167-174.
PHI L T H， SARI I N， WIJAYA Y T， et al. Ginsenoside Rd inhibits the metastasis of colorectal cancer via epidermal growth factor receptor signaling Axis［J］. IUBMB Life， 2019， 71（5）： 601-610.
LI H， HUANG N， ZHU W， et al. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2［J］. BMC Cancer， 2018， 18（1）： 579.
LEE H， LEE S， JEONG D， et al. Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells［J］. J Ginseng Res， 2018， 42（4）： 455-462.
LIU G W， LIU Y H， JIANG G S， et al. The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism［J］. Hum Cell， 2018， 31（3）： 189-198.
ZHANG K， LI Y. Effects of ginsenoside compound K combined with cisplatin on the proliferation， apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer［J］. Pharm Biol， 2016， 54（4）： 561-568.
CHAE S， KANG K A， CHANG W Y， et al. Effect of compound K， a metabolite of ginseng saponin， combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo［J］. J Agric Food Chem， 2009， 57（13）： 5777-5782.
QIN J， LI R， RAES J， et al. A human gut microbial gene catalogue established by metagenomic sequencing［J］. Nature， 2010， 464（7285）： 59-65.
MESSAOUDI M， LALONDE R， VIOLLE N， et al. Assessment of psychotropic-like properties of a probiotic formulation （Lactobacillus helveticus R0052 and Bifidobacterium longum R0175） in rats and human subjects［J］. Br J Nutr， 2011， 105（5）： 755-64.
KAOUTARI A E， ARMOUGOM F， GORDON J I， et al. The abundance and variety of carbohydrate-active enzymes in the human gut microbiota［J］. Nat Rev Microbiol， 2013， 11（7）： 497-504.
0
浏览量
430
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：10154 今日访问量：17